A phase Ib, open-label, multicenter trial of intravenous INO-1001 plus oral temozolomide to evaluate the tolerability, safety, and pharmacokinetics in subjects with newly-diagnosed or recurrent unresectable stage III or stage IV melanoma

Trial Profile

A phase Ib, open-label, multicenter trial of intravenous INO-1001 plus oral temozolomide to evaluate the tolerability, safety, and pharmacokinetics in subjects with newly-diagnosed or recurrent unresectable stage III or stage IV melanoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2014

At a glance

  • Drugs INO 1001; Temozolomide
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 09 Mar 2009 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov.
    • 13 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top